AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II study of erlotinib and AMG 102 in previously treated subjects with
advanced NSCLC. Subjects will be enrolled with recurrent or progressive advanced stage NSCLC
that has been treated with at least one and a maximum of two prior chemotherapy regimens. The
Phase I part of the study will enroll 8-16 subjects with the Phase II part enrolling 21-45
subjects.
The Phase I part of the study is designed to determine how safest the combination of AMG 102
and erlotinib is and the recommended dose for the Phase II part. The Phase II part is to
determine whether the combination of AMG102 and erlotinib works enough to warrant further
interest in this combination.